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Abstract: This case report originated from a case of neonatal multisystemic juvenile xanthogranuloma (JXG). The patient presented 
with blue muffin rush, cervical mass, bone destruction, lung nodule, hepatosplenomegaly, and coagulopathy and was successfully treated 
with Langerhans cell histiocytosis (LCH) based chemotherapy treatment. Similar cases in literature were reviewed and it seems that 
JXG, a relatively benign entity, when presented in its systemic form with liver involvement, could have an aggressive course and por-
tend quite poor prognosis. Challenges and special consideration of the diagnosis, treatment, and future case observation are discussed.
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Introduction
Juvenile xanthogranuloma (JXG) is a histiocytic dis-
order most commonly present in the first two decades 
of life, especially in the neonatal period and first year 
of life. It is principally a solitary cutaneous lesion with 
occasional multifocal or multisystemic   involvement. 
It  has  a  male  predominance.  Prognosis,  generally 
speaking, is good except when there is deep or multi-
systemic involvement. Three large clinicopathologic 
studies are available.1–3
The spectrum of histological subtypes are nicely 
summarized by Janssen et al.2 Early JXG typically 
presents within compact sheet-like histiocytic infil-
trate,  with  or  without  scattered  eosinophils,  some-
times mimicking Langerhans cell histiocytosis (LCH). 
Touton-type giant cells are generally absent but can 
be detected occasionally. Classic JXG, on the other 
hand, typically has foamy histiocytes with abundant 
cytoplasm  and  fine  cytoplasmic  vacuolation;  spec-
trum of fully developed Touton giant cells is present, 
but giant cells of Langerhans type or foreign body 
type are also possible. The late or transitional sub-
type typically shows predominance of single sheets 
of cells reminiscent of benign fibrous histiocytoma 
with the addition of foamy histiocytes and giant cells. 
Combinations of these subtypes are possible.
A distinctive immunohistochemistry staining pat-
tern  includes:  positive  CD68,  alpha-1  antitrypsin, 
factor XIIIa, and lysozyme; S100 and CD1a are typi-
cally  negative,  in  contrast  to  its  cousin  Langerhans 
cell   histiocytosis. In electron microscopy studies, JXG 
shows no Birbeck granules as in LCH. Forms of sys-
temic disease are rare and they have significant clinical 
implications, as summarized by Freyer and Dehner.4 
The case reported here is a newborn with multisystemic 
JXG involvement, illustrating the difficulties and chal-
lenges encountered diagnostically and therapeutically.
case Report
The patient is a 5-week-old, former 35-week infant who 
was admitted for evaluation of pancytopenia, transfu-
sion dependence, and massive   hepatosplenomegaly. 
He was born from normal spontaneous vaginal deliv-
ery with no maternal complications. It was noted that 
he had a blueberry muffin rash at birth.
During his first month stay at nursery (NICU for 
prematurity), he was doing well and was eating and 
thriving.
Physical examination was remarkable for left pos-
terior  cervical  mass  (suboccipital  region)  that  was 
firm and diffuse, not discrete like a lymph node. The 
abdomen was soft, nontender, distended with marked 
hepatosplenomegaly down to the level of the umbi-
licus for the liver and spleen. There was an easily 
reducible umbilical hernia present. The rest of physi-
cal examination was within normal limits.
Diagnostic workup with abdominal ultrasound ini-
tially showed hepatomegaly with multiple hypoechoic 
lesions  in  the  liver  along  with  splenomegaly  and 
ascites (Figure 5). Several CT scans confirmed these 
findings and found no other masses in the   abdomen. 
  Evaluation  of  the  chest  revealed  a  single  right 
middle  lobe    nodule.Evaluation  of  the  lymph  node 
showed a mass adjacent to the left posterior cervical 
Figure 1. Juvenile xanthogranuloma. Foamy histiocytes aggregates with 
classic teuton giant cells embedded.
Figure 2. Note focally prominent hemosiderin deposit and presence of 
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  musculature and there was suggestion of destruction 
of the adjacent occipital bone and possible intracra-
nial   extension. MRI of the brain showed destruction 
of the left occiput with likely lesion of the left sigmoid 
sinus and abutment of the left internal carotid artery 
with encroachment of the spinal foramen without loss 
of flow in the artery or extension into the spinal cord. 
The bone marrow biopsy revealed a normocellular 
marrow with a decreased left shift. Other tests per-
formed for these masses, including HVA and VMA, 
were all normal. The TORCH workup was negative. 
The differential for these various lesions, including 
the blueberry muffin spots, which were thought to be 
either in situ extramedullary hematopoiesis or super-
ficial tumor metastases, included neuroblastoma and 
congenital leukemia.
Biopsy  of  the  neck  mass  revealed  a  histiocytic 
lesion;  the  lesional  cells  were  mostly  polygonal 
(some with quite visible vacuolation) with indistinct 
borders,  plus  abundant  classic  Touton  giant  cells. 
  Scattered  inflammatory  cells,  mostly  lymphocytes, 
were observed as well. Focal areas showed significant 
hemosiderin deposits (Figure 1–3). Entrapped nerve 
bundles and large caliber blood vessels were noted. 
The staining pattern of lesion cells was as follows: 
S100 negative, CD1a negative; CD68 positive, cyto-
plasmic,  alpha-1  antitrypsin  positive,  cytoplasmic, 
lysozyme positive (strong, patchy, and cytoplasmic). 
Additional stains included: CD34, CD35, CD21, and 
CD20  negative;  CD4  positive  membranous;  factor 
XIIIa strong   positive; fascin positive; and cytoplasmic 
(Figure  4). The  diagnosis  of  juvenile  xanthogranu-
loma was established.
The patient was put on protocol LCH-III for the 
treatment of JXG, following the arm for high risk 
group. The chemotherapy agents included prednisone, 
Vinblastine, 6-MP, and Methotrexate. Coagulopathy 
and  pancytopenia  was  managed  symptomatically. 
The patient was relatively stable but had an episode 
of line infection. As this brief report was written, he 
has been off therapy for twenty months. At this point, 
he is doing well without any concerns and has begun 
walking and on regular followup. On physical exami-
nation, he was alert and well appearing; head and 
neck exam was remarkable only for a small bruise on 
his cheek; no mass was palpable in the left occipital 
region any longer. There was no lymphadenopathy. 
Lungs were clear throughout. Heart showed regular 
rate and rhythm without murmur. Abdomen examina-
tion demonstrated the liver was down 4 cm and spleen 
Figure 3. Teuton giant cell morphology is best appreciated on touch prep 
slides.
Figure 4. The immunohistochemistry staining pattern: (A) Fascin upper left 
(B) CD68 upper right (c) CD4 lower left (D) Factor XIIIa lower right.
Figure 5. The liver ultrasound image showed multiple hypoechoic lesions.Fan and Sun
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tip was palpable 3 to 4 cm. His gait was considered 
wide based but age appropriate and the remainder of 
his exam was unremarkable. Pancytopenia had recov-
ered and complete blood count (CBC) results were 
within normal ranges.
Radiology followup showed decrease in size of the 
left occipital soft tissue mass abutting the skull base; 
lung lesion and low density foci distributed through-
out the liver were stable; hepatomegaly and splenom-
egaly were also stable.
Discussion
Similar cases have been documented in medical lit-
erature and many of them behaved aggressively. It is 
fair to state that when JXG has liver Involvement, it is 
a relatively benign disease in its worst form. In 1996, 
Dehner reported eight out of 34 patient with systemic 
JXG had liver involvement, two neonates died with 
systemic  JXG,  among  which  one  had  liver/spleen 
involvement (patient number 19).4 In   Dehner’s 2003 
survey, liver involvement claimed two out of only 
three deaths in 174 cases (patients number 2 and 7).1 
The Kiel study reported 129 patients with five cases 
of systemic JXG, in which the only one death (with 
disease) was the one with liver and spleen involve-
ment (patient number 5).2 In 2008, Haughton reported 
a case of “blueberry muffin baby” that proved to be 
a systemic JXG with skin and liver involvement, and 
who  ended  up  needing  liver  transplant.5  But  suc-
cessfully treated cases are available, summarized by 
Stover in 20086 So the pattern appears to be that the 
systemic JXG with liver involvement carries the worst 
prognosis implications, even though, as a whole, the 
systemic JXG group generally still tends to be prog-
nostically optimistic.
It has been observed that extracutaneous JXG tends 
to have less or absent multinucleated giant cells, but 
our case is certainly the opposite. This case has florid 
classic Touton giant cells. So the lesson still is, the 
microscopic appearance of this entity is varied greatly 
and entertain the high suspicion with any histiocytes-
rich lesion is essential.
From a cytogenesis point of view, JXG is related 
to LCH but has always been considered as a distinc-
tive entity. The evolution of the hypotheses of its cel-
lular origin is such an interesting topic that almost 
every study, major or small, paid some attention to it. 
Briefly, the earliest speculation in 1912 was that it has 
an endothelial origin;7 in 1954, its histiocytic nature 
was recognized and the consensus was to place this 
entity under non-Langerhans histiocytosis group as 
archetype of non-Langerhans histiocytosis,8–10 with 
factor XIIIa+  dermal  dendrocytes  as  the  strongest 
candidate  originating  cells;11  however,  this  con-
cept has been challenged recently and plasmacytoid 
monocyte has been proposed as the putative origin 
of JXG.12
Due to the rarity of the systemic JXG, treatment proto-
cols have followed that use for LCH. Histiocyte Society 
has a clinical stratification of LCH based on the extent of 
the disease. For patients with multiorgan involvement, 
LCH-III protocol is currently the most common treat-
ment strategy, which was first suggested by Nakatani 
et al.13 Experience with treating systemic JXG is avail-
able through a recent review by Stover, in which a LCH 
based regimen seems to have been justified.6
Clinical trials can be found on the website: H-9926-
LCH  III:  Treatment  Protocol  of  the  Third  Inter-
national  Study  for  Langerhans  Cell  Histiocytosis: 
http://  clinicaltrials.gov/ct2/show/NCT00488605. The 
treatment does not always go well even though JXG 
generally carries a favorable prognosis even for its 
systemic forms. Patients sometime did not response, 
some died from the disease. Cladribine appears to be a 
reasonable second line option. In one report, an infant 
with systemic JXG with CNS involvement who first 
could not tolerate prednisolone and later failed vin-
blastine was treated successfully with Cladribine.14 
The similar positive responses have been reported in 
recurrent LCH treatments.15,16
Disease  activity  monitoring  is  also  part  of  the 
  Histiocyte Society‘s recommendation.17
conclusion
Because of the rarity and wide spectrum of manifes-
tation, systemic JXG is often not considered in the 
initial differential diagnosis as happened in this case. 
Therefore, high degree of clinical suspicion and open 
mindedness is warranted when patients present with 
multisystemic symptoms suggestive of malignancy, 
especially with cases of similar presentation in the 
neonatal age group. Besides the consideration of neu-
roblastoma, so called “blueberry muffin rash” may 
also hint to the possible existence of systemic JXG.
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worst form of systemic JXG with a more aggressive 
behavior and worse prognosis than other similar cases 
in  the  same  category;  intensified  treatment,  close 
monitoring, and followup is warranted. A LCH III 
based regimen is currently recommended and worked 
well in our case; if no satisfactory response is gener-
ated, an alternative treatment such as Cladribine may 
be tried.
Overall, our knowledge of systemic JXG is still 
very limited; more experience with its diagnosis and 
treatment is necessary and expected. More individual 
cases reports and multicenter coordination should be 
encouraged.
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